Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PTGER2 encodes a receptor for prostaglandin E2, a metabolite of arachidonic acid which has different biologic activities in a wide range of tissues. Additionally we are shipping PTGER2 Kits (24) and PTGER2 Proteins (5) and many more products for this protein.
Showing 10 out of 107 products:
Bat Polyclonal PTGER2 Primary Antibody for ELISA, IHC - ABIN4348390
Kotarska, Lenartowicz, Przybyło, Gołas, Styrna: Increased prostaglandin E₂-EP2 signalling in cumulus cells of female mice sired by males with the Y-chromosome long-arm deletion. in Reproduction, fertility, and development 2013
Prostaglandin E receptor subtype 2 (EP2 (show SPAG11A Antibodies); Ptger2) deficiency suppressed nuclear factor kappaB (NF-kappaB (show NFKB1 Antibodies)) activation in intracranial arteries 4 and 8 weeks after intracranial aneurysm induction.
neuronal EP2 receptor activation by PGE2 protects brain against intracerebral hemorrhage injury in middle-aged mice through its anti-inflammatory and anti-oxidant effects and anti-MMP-2 (show MMP2 Antibodies)/9 activity
data demonstrate that endogenous PGE2, EP2 (show SPAG11A Antibodies) receptors, and EPAC (show RAPGEF3 Antibodies) are prerequisites for maximal LPS (show TLR4 Antibodies)-induced IL-33 (show IL33 Antibodies) expression and that exogenous PGE2 can amplify IL-33 (show IL33 Antibodies) production via EP2 (show SPAG11A Antibodies) and EP4 (show PTGER4 Antibodies) receptors.
The data presented highlight a key role for EP2 (show SPAG11A Antibodies) and EP4 (show PTGER4 Antibodies) receptors in microvascular leak induced by PGE2.
Exposure of macrophages to cyclooxygenase (COX-2 (show COX2 Antibodies)) inhibitors RhoA (show RHOA Antibodies) and LA-4 cells to antagonists of prostaglandin E2 (PGE2) receptor , PGD2 (show PTGDS Antibodies) receptors or the hepatocyte growth factor (HGF (show HGF Antibodies)) receptor c-Met (PHA (show LBR Antibodies)-665752), reversed EMT (show ITK Antibodies) inhibition by the conditioned medium
EP2 (show SPAG11A Antibodies) deficiency in MCs (show SMCP Antibodies) augmented TGF-beta1 (show TGFB1 Antibodies)-induced fibronectin (FN (show FN1 Antibodies)), cyclooxygenase-2 (COX2 (show PTGS2 Antibodies)), and CyclinD1 expression. Silencing of EP2 (show SPAG11A Antibodies) also strengthened TGF-beta1 (show TGFB1 Antibodies)-induced extracellular-signal-regulated kinase 1/2 (show MAPK3 Antibodies) (ERK1/2 (show MAPK1/3 Antibodies)) phosphorylation
autocrine prostaglandin E2 signaling through EP receptors is essential for optimal CD4 (show CD4 Antibodies)(+) T-cell activation.
the blockade of EP2 (show SPAG11A Antibodies) and EP4 (show PTGER4 Antibodies) promotes mouse survival after cryptococcus infection by promoting the production of cytokines via TLR4 (show TLR4 Antibodies), as well as the enhanced M1 polarization of alveolar macrophages
COX-2-derived PGE2 inhibits IL-10 expression in brain microglia through a novel EP2- and beta-arrestin-dependent signaling pathway.
Cardiac inflammation is reduced in EP-2 (show SPAG11A Antibodies)-/- mice.
in breast cancer cells overexpression of S1P3 (show S1PR3 Antibodies) and its activation by S1P (show MBTPS1 Antibodies) has pro-inflammatory and pro-metastatic potential by inducing COX-2 (show COX2 Antibodies) expression and PGE2 signaling via EP2 (show SPAG11B Antibodies) and EP4 (show PTGER4 Antibodies).
EP2 (show SPAG11B Antibodies) and EP3 (show PTGER3 Antibodies) receptors are involved in tolerance induction through IL-10 (show IL10 Antibodies) production by tol-DCs.
This is the first report that PGE2 -induced uPAR (show PLAUR Antibodies) expression, which stimulates invasiveness of human gastric cancer AGS (show JAG1 Antibodies) cells, is mediated by the EP2 receptor-dependent Src (show SRC Antibodies)/EGFR (show EGFR Antibodies)/JNK1 (show MAPK8 Antibodies)/2, Erk1/2 (show MAPK1/3 Antibodies)/AP-1 (show FOSB Antibodies), and Src (show SRC Antibodies)/EGFR (show EGFR Antibodies)/JNK1 (show MAPK8 Antibodies)/2, Erk1/2 (show MAPK1/3 Antibodies)/NF-kappaB (show NFKB1 Antibodies) cascades.
These results indicate that the ICL2 region of the EP2 receptor is its potential interaction site with Galphas (show GNAS Antibodies), and that the aromatic side chain moiety at position 143 is a determinant for the accessibility of the ICL2 to the Galphas (show GNAS Antibodies) protein.
EP2 (show SPAG11B Antibodies) receptors seem to be able to distinguish endogenous ligands PGD2 (show PTGDS Antibodies), PGE2 or prostaglandin F2alpha better than DP receptors.
EP2 receptor activation protects against endoplasmic reticulum stress-dependent mitochondrial apoptosis through down-regulation of p53 (show TP53 Antibodies).
that the expression of ERG (show ERG Antibodies) in prostate cancer is linked to the expression of IL-6 (show IL6 Antibodies) mediated by the prostanoid receptor EP2 (show SPAG11B Antibodies)
mPGES-1 (show PTGES Antibodies) is downregulated via EGR1 (show EGR1 Antibodies) and has a role in caffeine inhibition on PGE2 synthesis of HBx hepatocytes
Altered expression of EP2 (show SPAG11B Antibodies) in patients with aspirin-exacerbated respiratory disease contributes to deficient induction of IL-1RI, reducing the capacity of IL-1beta (show IL1B Antibodies) to increase COX-2 (show COX2 Antibodies) and mPGES-1 (show PTGES Antibodies) expression, which results in low PGE2 production
Reduced EP2 receptor expression results in resistance to the antiproliferative effects of EP2 (show SPAG11B Antibodies) signaling in nasal polyp fibroblasts from subjects with AERD and support a role for EP2 (show SPAG11B Antibodies) signaling in the aberrant growth of nasal polyp tissue.
Data suggest that lysophosphatidic acid (LPA (show PLG Antibodies)) up-regulates expression of SLCO2A1 (show SLCO2A1 Antibodies) (prostaglandin [PG] transporter), PTGER2/PTGER4 (show PTGER4 Antibodies) (PG receptors EP2 (show SPAG11A Antibodies)/EP4 (show PTGER4 Antibodies)), and mPGES1 (show PTGES Antibodies)/cPGES (show PTGES3 Antibodies) (microsomal/cytosolic PG E synthases) in luteal cells.
Data suggest that estradiol up-regulates mRNA and protein expression of 3 prostanoid receptors in oviduct smooth muscle: EP2/PTGER2 (prostaglandin E receptor 2); EP4/PTGER4 (show PTGER4 Antibodies) (prostaglandin E receptor 4); and FP/PTGFR (prostaglandin F2alpha receptor (show PTGFR Antibodies)).
EP2 (show SPAG11A Antibodies) is the major cAMP-generating PGE (show LIPF Antibodies)(2) receptor expressed and regulated in the bovine uterus during the estrous cycle and early pregnancy.
COX-2 (show PTGS2 Antibodies) and FP receptor (show PTGFR Antibodies) contribute via changes in amount and distribution to mechanisms associated with parturition.
Quantitative RT-PCR revealed significant higher expression of EP2 (show SPAG11A Antibodies) and EP4 (show PTGER4 Antibodies) in the pre-ovulatory phase compared with the luteal phase in the bovine oviduct
This gene encodes a receptor for prostaglandin E2, a metabolite of arachidonic acid which has different biologic activities in a wide range of tissues. Mutations in this gene are associated with aspirin-induced susceptibility to asthma.
, prostaglandin E receptor 2 (subtype EP2), 53kDa
, prostaglandin E2 receptor EP2 subtype
, EP2 receptor
, PGE receptor EP2 subtype
, PGE2 receptor EP2 subtype
, prostaglandin E receptor 2 (EP2 subtype)
, prostaglandin E receptor EP2 subtype
, prostaglandin E receptor subtype EP2
, prostanoid EP2 receptor
, PGE receptor, EP2 subtype
, prostaglandin E2 receptor type 2
, prostaglandin E2 receptor subtype EP2